Celgene Corporation

Release Summary

Celgene presented at SABCS findings of tnAcity, which found a first-line weekly combo regimen of ABRAXANE/carboplatin had longer PFS vs ABRAXANE/gemcitabine or carboplatin/gemcitabine in mTNBC patient

Celgene Corporation